Xiaobin Wu Sells 51,921 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu sold 51,921 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $261.59, for a total value of $13,582,014.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96.

Beigene Price Performance

Shares of NASDAQ:ONC opened at $247.07 on Friday. Beigene, Ltd. has a 1-year low of $126.97 and a 1-year high of $287.88. The company has a market cap of $24.18 billion, a PE ratio of -29.98, a PEG ratio of 7.73 and a beta of 0.65. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ONC. Macquarie increased their price objective on Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $207.00 to $320.00 in a report on Monday, March 3rd.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.